Claims
- 1. A compound having the general structure:
- 2. The compound of claim 1 where the compound is selected from the group consisting of:
- 3. A compound having the following general structure:
- 4. The compound of claim 3 wherein in the compound is selected from the group consisting of:
- 5. An analog of anandamide methylated at carbon 16 and having a chemical structure selected from the group consisting of:
- 6. An analog of arvanil having a chemical structure selected from the group consisting of:
- 7. A method for selectively blocking CB1 receptors in a cell or host without blocking CB2 and VR1 receptors, comprising the step of providing said cell or said host with a compound selected from the group consisting of
- 8. A method for increasing the potency of an anandamide or arvanil analog at CB1 receptors, comprising the step of brominating or cyanating an anandamide or arvanil analog at a C-20 position of said anandamide or arvanil analog.
- 9. The method of claim 8, wherein said anandamid or arvanil analog is an arvanil analog and further comprising the step of methylating said arvanil analog at a C-16 position.
- 10. A method of managing pain in a patient in need thereof, comprising the step of
administering to said patient a compound as recited in any of claims 1, 3, 5 or 6, in a quantity sufficient to manage said pain.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation in part of pending United States patent application Ser. No. 10/170,204, filed Jun. 13, 2002, the complete contents of which is hereby incorporated by reference.
Government Interests
[0002] This invention arose while performing research under grants from the National Institutes of Health (NIH) DA 09789, DA 07027, and DA 08904. The U.S. Government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60299199 |
Jun 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10170204 |
Jun 2002 |
US |
Child |
10365607 |
Feb 2003 |
US |